CD274 and non-small cell lung carcinoma: In 2016, the FDA also approved the use of Pembrolizumab (anti-PD-1) as first- or second-line monotherapy treatment in NSCLC patients and Atezolizumab (anti-PD-L1) for patients with disease progression during or following platinum-based chemotherapy [19,20,21,22].